OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Psychopharmacology is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
The dosing procedure that “makes the poison”: Comparing the effects of single versus cumulative alcohol administration methods on emotion recognition	262
Psychedelics and the ‘inner healer’: Myth or mechanism?	187
Which are the demographic and clinical characteristics of patients who respond to subcutaneous esketamine?	107
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	94
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	74
5-HT_1B receptor agonist attenuates cocaine self-administration after protracted abstinence and relapse in rats	71
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	65
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	57
The chronic effects of a combination of herbal extracts (Euphytose^®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	56
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	54
Relationship between depression, prefrontal creatine and grey matter volume	53
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	52
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	51
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	49
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	47
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	44
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	43
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	43
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	41
Effects of 31 recombinant CYP2C19 variants on clomipramine metabolism in vitro	41
The Journal of Psychopharmacology: La Plus ça change. . .	40
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	39
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	36
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	36
Repurposing psychopharmacology: A two-way street?	36

Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	35
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	34
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	33
Not too quick on “Debunking the myth of ‘Blue Mondays’”	32
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	32
The New Zealand drug harms ranking study: A multi-criteria decision analysis	31
Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk	30
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	30
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	30
Elevated C-reactive protein among symptomatic youth with bipolar disorder	28
Postpartum depression: A role for psychedelics?	26
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	26
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	25
Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant: A randomized, placebo-controlled crossover study	25
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α₂-adrenoceptor sensitivity	25
Impact of psychedelics on craving in addiction: A systematic review	24
The low risk for early renal damage during lithium treatment has not changed over time	24
Increasing dietary choline attenuates spatial memory deficits resulting from exposure to the chemotherapeutic agents cyclophosphamide and doxorubicin	23
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	23
Altered amygdala-cortical connectivity in individuals with Cannabis use disorder	22
The mechanism of action of clozapine	22
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19/CYP2D6 genes play a role? A UK population-based study	22
Drug–drug interactions involving classic psychedelics: A systematic review	22
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	21
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis	21
Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia	20
Effect of medication on risk of traumatic brain injury in patients with bipolar disorder: A nationwide population-based cohort study	20
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR₉) measure of suicidal risk	20
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	20
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	20
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	19
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	19
The antidepressant effect and safety of non-intranasal esketamine: A systematic review	19
Insufficiency of ventral hippocampus to medial prefrontal cortex transmission explains antidepressant non-response	19
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	18
Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology	18
The effects of reserpine on depression: A systematic review	18
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	17
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	17
Effect of CannEpil^® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	17
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	17
Psilocybin for clinical indications: A scoping review	17
The effects of selective serotonin reuptake inhibitors on memory functioning in older adults: A systematic literature review	16
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	16
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	16
Older adults in psychedelic-assisted therapy trials: A systematic review	15
Neuropsychological performance in young adults with cannabis use disorder	15
Modafinil: A closer look at its theoretical toxicological potential	15
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	15

Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial	15
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	15
Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin®) in adults experiencing high stress and fatigue in a randomized, double-blin	14
Episodic foresight is impaired following acute alcohol intoxication	14
Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	14
Comparative safety of chronic versus intermittent benzodiazepine prescribing in older adults: A population-based cohort study	14
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	14
Examining the role of systemic chronic inflammation in diet and sleep relationship	14
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	14
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	14
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects	14
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	14
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	13
Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review	13
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	13
The association between N-methyl-d-aspartate receptor availability and glutamate levels: A multi-modal PET-MR brain imaging study in first-episode psychosis and healthy controls	13
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	13
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	13
Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate	13
Common protein networks for various drug regimens of major depression are associated with complement and immunity	13
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	13
A letter to the editor, associated with the article entitled “Efficacy and tolerability of combination treatments for major depression: Antidepressants plus second-generation antipsychotics vs esketam	13
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls	13
Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD)	13
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	13
Aberrant inhibitory processing in the somatosensory cortices of cannabis-users	12
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	12
The psychedelic effects of cannabis: A review of the literature	12
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	12
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	12
Effects of CYP2D64* polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder	12
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	11
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	11
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	11
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	11
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	11
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	11
Ketamine: A new chapter for clinical psychopharmacology?	11
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	11
Intoxication without anticipation: Disentangling pharmacological from expected effects of alcohol	11
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	11
Effect of selective serotonin reuptake inhibitor discontinuation on anxiety-like behaviours in mice	11
Effects of acute lysergic acid diethylamide on intermittent ethanol and sucrose drinking and intracranial self-stimulation in C57BL/6 mice	11
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	11
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	11
The psychopharmacology of mood disorders	11
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	10
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	10
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	10
Clinical correlates of early onset antipsychotic treatment resistance	10
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	10
Role of serotonin in modulation of decision-making in Parkinson’s disease	10
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	10
Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016	10